CClinicalTrials.gg
CompletedNCT05215522Updated May 15, 2023

Tele BCI-FES for Upper -Limb Stoke Rehabilitation

An interventional study of The BCI-FES Intervention in Stroke, sponsored by University of Sheffield. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by University of Sheffield · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to identify whether stroke survivors can intentionally modulate their brain signals for controlling an FES device to produce arm movements for home based rehabilitation. The study also assess the participants acceptability of this new home-based rehabilitation.

Read the detailed description

Movements of different parts of the body, including the arm, start when the brain produces specific electrical signals. Sometimes after a stroke, even though the person intends to move the arm, the arm will not move or will only move partly. The brain continues to produce electrical signals after stroke, but when the signals are weak the arm does not move. Brain-computer interface (BCI), is a method of utilising the brain signals to produce useful outputs via computers. One type of BCI is BCI Functional Electrical Stimulus (BCI-FES) which is a device that can detect these brain signals produced during the intention to move the weak arm after a stroke. It then uses these signals to trigger an electrical stimulator. The electrical stimulator then stimulates the muscles in the weak arm to produce the desired arm movement. Recent studies show that rehabilitation using this device has given better results when compared with conventional rehabilitation approaches. However, the BCI-FES devices currently available are bulky and participants need to come to the hospital or laboratory to receive the treatment. Our project aims to develop a BCI-FES device, called Tele BCI-FES that can be used at stroke participant's home. The investigators are using techniques like machine learning to make the Tele BCI-FES quick and simple to set up, easy to use and effective. This study aims to investigate if the proposed Tele BCI-FES device is a feasible and acceptable intervention for post-stroke rehabilitation.

02

Conditions studied

  • Stroke

Keywords

  • Brain-computer interface
  • functional electrical stimulation
  • Tele-rehabilitation
  • stroke rehabilitation
03

In context

Lead sponsor

University of Sheffield is the lead sponsor of 74 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18 and above.

(2) Experienced an ischaemic or haemorrhagic stroke more than 6 months ago.

(3) Arm weakness interfering with activities of daily living.

(4) Fugl-Meyer score of upper limb\<45.

(5) Caregiver is willing to assist with trial by helping to deliver intervention.

(6) Cognitive and language abilities to understand and participate in the study protocol.

(7) Can maintain sitting with or without support for 1 hour continuously.

(8) Able to give consent and understand instructions.

Exclusion criteria

Exclusion criteria:

  1. Cognitive impairment that would interfere with their ability to comply with the experimental protocol or provide informed consent;
  2. Dermatological, rheumatologic or orthopaedic illnesses of the affected arm interfering with movement of the elbow;
  3. Pre-existing severe systemic disorders like cardiovascular disease; active cancer or renal disease; end stage pulmonary or cardiovascular disease; psychiatric illness including severe alcohol or drug abuse
  4. Inability to perform the baseline assessments;
  5. Severe tactile hypersensitivity;
  6. Participation in other, upper limb rehabilitation studies
  7. Within 12 weeks of receiving Botulinum toxin injections;
  8. History of epilepsy
  9. Pace maker or any other implanted devices
  10. Pregnancy
  11. Severe dystonia/spasm
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    The BCI-FES Intervention

    The BCI-FES device will be used by all participants.

    Device: The BCI-FES Intervention

Interventions

  • DeviceThe BCI-FES Intervention

    To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.

06

What researchers measure

Primary outcomes

  1. Evaluate the feasibility of the proposed system through the ability of participants to control the Tele BCI-FES

    To evaluate whether the participants can effectively control FES using the developed remote BCI system (Success: the BCI accuracy of more than 70% in at least 7 out of 9 sessions).

    Time frame: within 10 minutes after experimental session

  2. Evaluate the usability and acceptability of the proposed system based on the number of participants completing each TeleBCI-FES intervention session

    Number of participants completing each TeleBCI-FES intervention session (Success: 7 participants completed 8 or more of 12 TeleBCI-FES sessions)

    Time frame: through study completion, an average of 5 weeks

  3. Recruitment rate

    To measure the acceptability of the proposed rehabilitation

    Time frame: Pre-intervention

Secondary outcomes

  1. Fugl-Meyer Assessment

    It is the most frequently used outcome scales to measure post stroke motor recovery of the upper extremity on a scale of 0-60 (best).

    Time frame: Pre-intervention and up to 5 weeks

  2. Action Research Arm Test

    It is a 19 item observational measure used to assess upper extremity performance on a scale of 0 - 57 (best).

    Time frame: Pre-intervention and up to 5 weeks

  3. Modified Ashworth Scale

    This looks at elbow and wrist flexors on predefined scale. The scale ranges from 0 to 4 (worst).

    Time frame: Pre-intervention and up to 5 weeks

  4. Medical Research Council grading

    This looks at assessing muscle strength from Grade 5 (normal) to Grade 0 (no visible contraction) and takes around 10 minutes to complete.

    Time frame: Pre-intervention and up to 5 weeks

  5. Leeds Arm Spasticity Scale-reference

    It is a measure of passive arm function, suitable for participants with spasticity and little or no active movement of the upper extremity. The score ranges from 0 (No difficulty) to 4 (Inability to perform the activity).

    Time frame: Baseline and up to 5 weeks

  6. Numerical rating Scale (NRS)

    It requires the participant to rate their pain on a defined scale from 0 (no pain) to 10 (the worst pain)

    Time frame: Pre-intervention and up to 5 weeks

  7. Pittsburgh Participation in Rehabilitation scale

    It is a clinician-rated measure on a 6-point Likert-type scale that quantifies individuals' participation in their therapy sessions, ranging from 1 (None: participant refused the entire session) to 6 (Excellent: participant participated in all sessions)

    Time frame: within 10 minutes after experimental session

  8. European Quality of List 5D-5L (EQ-5D-5L):

    It is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is assigned a rating based on the severity of the problems in that area (no problems walking, minor problems, moderate problems, severe problems, or inability to walk). The tool also includes an overall health scale, on which the participant chooses a number between 1 and 100 (best) to represent their health status.

    Time frame: Pre-intervention and .up to 5 weeks

Other outcomes

  1. Interviews

    A qualitative assessment of the effectiveness and acceptability of treatment for participants.

    Time frame: within 10 minutes after experimental session

07

Study locations

1 site
  • Sheffield Teaching Hospitals
    Sheffield, South Yorkshire S5 7AT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — The participant's data will be "pseudo-anonymized" and no identifiable information will be maintained with the study data because the participant will be issued a unique study number. Paper copies of consent forms will be kept in locked cupboards at the University of Sheffield's Physiological Signals and Systems lab. Electronic data will be entered and saved immediately on a password-protected University server. After the study is completed, anonymised EEG data and questionnaire data will be preserved for fifteen years at the University of Sheffield archiving facility. The results of this study will be published in peer-reviewed journals. The findings will be presented in BCI and rehabilitation conferences, as well as patient-public involvement meetings. The participants will not be identifiable from any report or publication placed in the public domain.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05215522
Lead sponsor
University of Sheffield
Collaborators
Sheffield Teaching Hospitals NHS Foundation Trust, Medical Research Council
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Jun 15, 2022
Primary completion
Nov 30, 2022
Completion
Dec 30, 2022
Last update
May 15, 2023

Study contacts

Mahnaz Arvaneh, PhD
principal investigator · University of Sheffield

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion